Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malek B Hannouf

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Breast (Edinburgh, Scotland)|August 31, 2020
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world studyAtul Batra, Malek B Hannouf, Noura Alsafar, et al.
Pharmacoeconomics|November 30, 2013
Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancerMalek B Hannouf, Bin Xie, Muriel Brackstone, et al.
Journal of Comparative Effectiveness Research|November 20, 2019
Letter to the EditorMalek B Hannouf, Dale Muzzey, Ralf Kronenwett, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
A Population-Based Study to Evaluate the Associations of Nodal Stage, Lymph Node Ratio and Log Odds of Positive Lymph Nodes with Survival in Patients with Small Bowel AdenocarcinomaAtul Batra, Shiying Kong, Malek B Hannouf, et al.
Clinical Colorectal Cancer|December 3, 2020
Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal CancerAtul Batra, Rodrigo Rigo, Malek B Hannouf, et al.
BMC Cancer|October 4, 2012
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancerMalek B Hannouf, Bin Xie, Muriel Brackstone, et al.
Plos One|June 30, 2012
Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancerMalek B Hannouf, Chander Sehgal, Jeffrey Q Cao, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021)Alda Aleksi, Kaiden D Jobin, Malek B Hannouf, et al.
The Pharmacogenomics Journal|May 28, 2019
Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancerMalek B Hannouf, Gregory S Zaric, Phillip Blanchette, et al.
Cancers|September 9, 2023
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature ReviewDanilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B Hannouf, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Breast (Edinburgh, Scotland)|August 31, 2020
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world studyAtul Batra, Malek B Hannouf, Noura Alsafar, et al.
Pharmacoeconomics|November 30, 2013
Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancerMalek B Hannouf, Bin Xie, Muriel Brackstone, et al.
Journal of Comparative Effectiveness Research|November 20, 2019
Letter to the EditorMalek B Hannouf, Dale Muzzey, Ralf Kronenwett, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
A Population-Based Study to Evaluate the Associations of Nodal Stage, Lymph Node Ratio and Log Odds of Positive Lymph Nodes with Survival in Patients with Small Bowel AdenocarcinomaAtul Batra, Shiying Kong, Malek B Hannouf, et al.
Clinical Colorectal Cancer|December 3, 2020
Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal CancerAtul Batra, Rodrigo Rigo, Malek B Hannouf, et al.
BMC Cancer|October 4, 2012
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancerMalek B Hannouf, Bin Xie, Muriel Brackstone, et al.
Plos One|June 30, 2012
Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancerMalek B Hannouf, Chander Sehgal, Jeffrey Q Cao, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Real-World Effectiveness of Capecitabine and Temozolomide Across Endocrine and Neuroendocrine Neoplasm Subtypes (ENENs): A Population-Based Cohort Study from Alberta, Canada (2011-2021)Alda Aleksi, Kaiden D Jobin, Malek B Hannouf, et al.
The Pharmacogenomics Journal|May 28, 2019
Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancerMalek B Hannouf, Gregory S Zaric, Phillip Blanchette, et al.
Cancers|September 9, 2023
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature ReviewDanilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B Hannouf, et al.
Pageof 2